化疗对肿瘤免疫功能影响的研究进展

被引：44

作者：

陈丽

焦顺昌

机构：

[1] 解放军总医院肿瘤内科

来源：

临床肿瘤学杂志 | 2011年 / 16卷 / 09期

关键词：

化学治疗; 肿瘤免疫;

D O I：

暂无

中图分类号：

R730.5 [肿瘤治疗学];

学科分类号：

100214 [肿瘤学];

摘要：

肿瘤的发生、发展及转归与机体免疫功能密切相关。化疗是肿瘤常规治疗手段,其在杀伤肿瘤细胞的同时,对机体免疫系统也有不同程度的杀伤和抑制作用。近年来研究发现,化疗对机体免疫格局的调整可能具有双向作用。因此,依据化疗后机体免疫功能的不同变化,调整相应的治疗方案,将化疗和机体免疫功能有机结合,将最终提高肿瘤的治疗效果。

引用

收藏

页码：853 / 856

页数：4

相关论文

共 18 条

[1]

Desirable cell death during anticancer chemotherapy.[J]..Annals of the New York Academy of Sciences.2010, 1

[2]

HPV 16-associated tumours: IL-12 can repair the absence of cytotoxic and proliferative responses of tumour infiltrating cells after chemotherapy [J].

Indrova, Marie ;

Bieblova, Jana ;

Rossowska, Joana ;

Kuropka, Piotr ;

Pajtasz-Piasecka, Elzbieta ;

Bubenik, Jan ;

Reinis, Milan .

INTERNATIONAL JOURNAL OF ONCOLOGY, 2009, 34 (01) :173-179

[3]

Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse [J].

Vicari, Alain P. ;

Luu, Rachel ;

Zhang, Ningli ;

Patel, Shobhna ;

Makinen, Shawn R. ;

Hanson, Douglas C. ;

Weeratna, Risini D. ;

Krieg, Arthur M. .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2009, 58 (04) :615-628

[4]

Occurrence of autoimmunity in a long-term survivor with metastatic colon carcinoma treated with a new chemo-immunotherapy regimen [J].

Correale, P. ;

Fioravanti, A. ;

Bertoldi, I. ;

Montagnani, F. ;

Miracco, C. ;

Francini, G. .

JOURNAL OF CHEMOTHERAPY, 2008, 20 (02) :278-281

[5]

Advances in chemotherapy for colorectal cancer [J].

Bernold, Dirk M. ;

Sinicrope, Frank A. .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2006, 4 (07) :808-821

[6]

CD4+CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer [J].

Okita, R ;

Saeki, T ;

Takashima, S ;

Yamaguchi, Y ;

Toge, T .

ONCOLOGY REPORTS, 2005, 14 (05) :1269-1273

[7]

Paclitaxel probably enhances cytotoxicity of natural killer cells against breast carcinoma cells by increasing perforin production [J].

Kubo, M ;

Morisaki, T ;

Matsumoto, K ;

Tasaki, A ;

Yamanaka, N ;

Nakashima, H ;

Kuroki, H ;

Nakamura, K ;

Nakamura, M ;

Katano, M .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2005, 54 (05) :468-476

[8]

Cellular immune profile in patients with non-small cell lung cancer after weekly paclitaxel therapy [J].

Sako, T ;

Burioka, N ;

Yasuda, K ;

Tomita, K ;

Miyata, M ;

Kurai, J ;

Chikumi, H ;

Watanabe, M ;

Suyama, H ;

Fukuoka, Y ;

Ueda, Y ;

Shimizu, E .

ACTA ONCOLOGICA, 2004, 43 (01) :15-19

[9]

The development of immunotherapies for non-small cell lung cancer [J].

Salgaller, ML .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2002, 2 (03) :265-278

[10]

T细胞亚群、NK细胞活性及Th1/Th2细胞因子漂移在FOLFOX化疗前后的动态变化 [J].

陈灵芝 ;

康云平 ;

王雪春 ;

黄常新 .

现代实用医学, 2009, 21 (07) :688-690